Autoimmune hemolytic anemia in a young man with acute hepatitis E infection

27), and CPS1 (A347S). This was performed in the patient with 12 month PFS during initial treatment. BPDCN is an aggressive hematologic malignancy with limited treatment options. Gemcitabine in combination with docetaxel was well-tolerated and achieved significant and sustained responses in this small retrospective series. This regimen showed antineoplastic activity both following allogeneic transplant and in the multiply-relapsed setting. This regimen should be considered for patients with relapsed disease and for those who are unable to tolerate aggressive induction therapy or enroll in a clinical trial. Based on this experience, further study is warranted, although the rarity of this disorder does hinder prospective investigation. Molecular contributors to this disorder may help guide future therapy in this challenging population, and more consistent investigations ofmutational burden and clonal development are needed.